EX-10.11



 Exhibit 10.11 

THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS. 
 WARRANT
AGREEMENT 
 To Purchase Shares of Preferred Stock of 

DANCE BIOPHARM, INC. 

Dated as of October 30, 2013 (the “Effective Date”) 

WHEREAS, Dance Biopharm, Inc., a Delaware corporation (as more fully defined below, the “Company”), has entered into a Loan and Security
Agreement of even date herewith (as modified, amended and/or restated and in effect from time to time, the “Loan Agreement”) with Hercules Technology III, L.P., a Delaware limited partnership (the “Warrantholder”);

 WHEREAS, the Company desires to grant to Warrantholder, in consideration for, among other things, the financial accommodations provided for in the Loan
Agreement, the right to purchase shares of Preferred Stock (as defined below) pursuant to this Warrant Agreement (this “Warrant” or this “Agreement”); 

NOW, THEREFORE, in consideration of the Warrantholder executing and delivering the Loan Agreement and providing the financial accommodations contemplated
therein, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE PREFERRED STOCK. 

For value received, the Company hereby grants to the Warrantholder the right to subscribe for and purchase from the Company, an aggregate number of fully paid
and non-assessable shares of the Preferred Stock equal to the quotient derived by dividing (a) $170,000 by (b) the Exercise Price (defined below). As used herein, the following terms shall have the following meanings: 

“Act” means the Securities Act of 1933, as amended. 

“Company” means Dance Biopharm, Inc., a Delaware corporation, and any successor or surviving entity that assumes the
obligations of the Company under this Agreement pursuant to Section 8(a). 
 “Charter” means the Company’s
Certificate of Incorporation or other constitutional document, as may be amended and/or restated and in effect from time to time. 

“Common Stock” means the Company’s common stock, $0.0001 par value per share, and any other class, series or other
designation of security into or for which such common stock is converted, substituted or exchanged pursuant to a reorganization, reclassification, recapitalization or similar transaction. 

“Exercise Price” means the Series A Price, subject to adjustment from time to time in accordance with the provisions of this
Warrant; provided, that if the Next Equity Round Price is lower than the then-effective Exercise Price, then the Exercise Price shall be the Next Equity Round Price from and after consummation of the Next Equity Round, subject to adjustment
thereafter from time to time in accordance with the provisions of this Warrant. 
 “Initial Public Offering” means the
initial underwritten public offering of the Company’s Common Stock pursuant to a registration statement under the Act, which registration statement has been declared effective by the Securities and Exchange Commission (“SEC”).








 “Merger Event” means any transaction or series of related transactions
involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the Company, (ii) the merger or consolidation of the Company into or with another person or entity (other than a merger or
consolidation effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the Company in their capacity as such immediately prior to such merger, consolidation or reorganization,
own less than a majority of the Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation or reorganization (or, if such Company stockholders beneficially own a majority of the
outstanding voting power of the surviving or successor entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company); or (iii) any sale or other transfer by the stockholders
of the Company of shares representing at least a majority of the Company’s then-total outstanding combined voting power. 

“Next Equity Round” means the first offering and sale by the Company, other than the Initial Public Offering, on or after the
date hereof, of shares of its convertible preferred stock or other equity securities to one or more investors for cash for financing purposes, in a single transaction or series of related transactions not registered under the Act, resulting in
aggregate gross cash proceeds received by the Company of at least $1,000,000. 
 “Next Equity Round Price” means the lowest
effective price per share for which shares of the Next Round Equity Series are sold and issued in the Next Equity Round. 
 “Next
Equity Round Series” means the class and/or series or other designation of the shares of convertible preferred stock or other equity securities sold and issued by the Company in the Next Equity Round. 

“Preferred Stock” means Series A Stock; provided, that if the Next Equity Round Price is lower than the then-effective
Exercise Price, then the Preferred Stock shall be the Next Equity Round Series from and after consummation of the Next Equity Round, and any other class, series or other designation of security into or for which such Next Equity Round Series is
converted, substituted or exchanged pursuant to a reorganization, reclassification, recapitalization or similar transaction; provided, further, that upon and after the occurrence of an event which results in the automatic or voluntary
conversion, redemption or retirement of all (but not less than all) of the outstanding shares of such Preferred Stock, including, without limitation, the consummation of an Initial Public Offering, then from and after the date upon which such
outstanding shares are so converted, redeemed or retired, “Preferred Stock” shall mean the Common Stock. 
 “Purchase
Price” means, with respect to any exercise of this Agreement, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares of Preferred Stock requested to be exercised under this Agreement pursuant to
such exercise. 
 “Series A Price” means $1.74 per share, as may be adjusted from time to time in accordance with the
provisions of this Warrant. 
 “Series A Stock” means the Company’s Series A Convertible Preferred Stock, $0.0001 par
value per share, containing the relative rights, powers, privileges and preferences as set forth in the Charter, and any other class, series or other designation of security into or for which such Series A Convertible Preferred Stock is converted,
substituted or exchanged pursuant to a reorganization, reclassification, recapitalization or similar transaction. 
 SECTION 2. TERM
OF THE AGREEMENT. 
 Except as otherwise provided for herein, the term of this Agreement and the right to purchase Preferred Stock as granted herein shall
commence on the Effective Date and shall be exercisable for a period ending upon the later to occur of (i) the tenth (10th) anniversary of the Effective Date, and (ii) if the
Initial Public Offering shall be consummated on or before the tenth (10th) anniversary of the Effective Date, the date that is five (5) years following the effective date of the
Company’s registration statement in connection with the Initial Public Offering. 

  
 2 








 SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or
from time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”),
duly completed and executed, together with payment of the Purchase Price (or election of Net Issuance) in accordance with the terms of this Agreement. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price (or election
of Net Issuance, as defined below) in accordance with the terms set forth below, and in no event later than three (3) days thereafter, the Company shall issue to the Warrantholder a certificate for the number of shares of Preferred Stock
purchased and shall execute the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject to future purchases, if any. 

The Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of all or a portion of the
Warrant for shares of Preferred Stock to be exercised under this Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined below (“Net Issuance”). If the
Warrantholder elects the Net Issuance method, the Company will issue Preferred Stock in accordance with the following formula: 
  

					
		 		    	X = Y(A-B)
		 		    	              A
			
	Where:	 	X =	    	the number of shares of Preferred Stock to be issued to the Warrantholder.
			
		 	Y =	    	the number of shares of Preferred Stock requested to be exercised under this Agreement.
			
		 	A =	    	the fair market value of one (1) share of Preferred Stock at the time of issuance of such shares of Preferred Stock.
			
		 	B =	    	the Exercise Price.

 For purposes of the above calculation, current fair market value of Preferred Stock shall mean with respect to each share of
Preferred Stock: 
 (i) if the exercise is in connection with an Initial Public Offering, and if the Company’s
registration statement relating to such Initial Public Offering has been declared effective by the SEC, then the fair market value per share shall be the product of (x) the initial “Price to Public” of the Common Stock specified in
the final prospectus with respect to the offering and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

(ii) if the exercise is after, and not in connection with, an Initial Public Offering, and: 

(A) if the Common Stock is traded on a securities exchange, the fair market value shall be deemed to be the product of
(x) the average of the closing prices over a five (5) trading day period ending three trading days before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into
which each share of Preferred Stock is convertible at the time of such exercise; or 
 (B) if the Common Stock is traded
over-the-counter, the fair market value shall be deemed to be the product of (x) the average of the closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) trading day period ending three trading days
before the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the time of such exercise; 

  
 3 








 (iii) if at any time the Common Stock is not listed on any securities exchange
or quoted in the over-the-counter market, the current fair market value of Preferred Stock shall be the product of (x) the highest price per share which the Company could obtain from a willing buyer (not a current employee or director) for
shares of Common Stock sold by the Company, from authorized but unissued shares, as determined in good faith by its Board of Directors and (y) the number of shares of Common Stock into which each share of Preferred Stock is convertible at the
time of such exercise, unless the Company shall become subject to a Merger Event, in which case the fair market value of Preferred Stock shall be deemed to be the per share value received by the holders of the Company’s Preferred Stock on a
common equivalent basis pursuant to such Merger Event. 
 Upon partial exercise by either cash or Net Issuance, the Company shall promptly issue an amended
Agreement representing the remaining number of shares purchasable hereunder. All other terms and conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective Date hereof. 

(b) Exercise Prior to Expiration. To the extent this Agreement is not previously exercised as to all Preferred Stock subject hereto,
and if the fair market value of one share of the Preferred Stock is greater than the Exercise Price then in effect, this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even if not surrendered) immediately before its
expiration. For purposes of such automatic exercise, the fair market value of one share of the Preferred Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this Agreement or any portion thereof is deemed
automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder of the number of shares of Preferred Stock, if any, the Warrantholder is to receive by reason of such automatic exercise. 

(c) Stockholder Agreements. Upon any exercise of this Warrant, Warrantholder shall, if the Company so requests in writing, become a
party to, by prompt execution and delivery to the Company of a counterpart signature page, joinder agreement, instrument of accession or similar instrument, the Company’s then-effective investor rights agreement, stockholders’ agreement
and/or each other agreement entered into among the Company and the holders of the outstanding shares of Preferred Stock (collectively, the “Stockholder Agreements”), in each case solely with respect to the shares of Preferred Stock
issued upon such exercise (and the shares of Common Stock, if any, issued upon conversion of such shares), solely to the extent that all holders of the outstanding shares of Preferred Stock are then parties thereto, and solely to the extent such
agreement is then by its terms in force and effect. 
 SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Preferred Stock to provide
for the exercise of the rights to purchase Preferred Stock as provided for herein, and shall have authorized and reserved a sufficient number of shares of its Common Stock to provide for the conversion of the shares of Preferred Stock issuable
hereunder. 
 SECTION 5. NO FRACTIONAL SHARES OR SCRIP. 

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the
Company shall make a cash payment therefor upon the basis of the then-fair market value of one share of Preferred Stock. 
 SECTION 6.
NO RIGHTS AS SHAREHOLDER/STOCKHOLDER. 
 This Agreement does not entitle the Warrantholder to any voting rights or other rights as a
shareholder/stockholder of the Company prior to the exercise of this Agreement. 

  
 4 








 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s initial address, for
purposes of such registry, is set forth below Warrantholder’s signature on this Agreement. Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 
 The
Exercise Price and the number of shares of Preferred Stock purchasable hereunder are subject to adjustment, as follows: 
 (a) Merger
Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of
preferred stock or other securities or property (collectively, “Reference Property”) that the Warrantholder would have received in connection with such Merger Event if Warrantholder had exercised this Agreement immediately prior to
the Merger Event. In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors) shall be made in the application of the provisions of this Agreement with respect to the rights and interests of the
Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments of the Exercise Price and adjustments to ensure that the provisions of this Section 8 shall thereafter be applicable, as nearly as
possible, to the purchase rights under this Agreement in relation to any Reference Property thereafter acquirable upon exercise of such purchase rights) shall continue to be applicable in their entirety, and to the greatest extent possible. Without
limiting the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the obligations of this Agreement; provided that if the Reference Property includes shares of stock or other
securities and assets of an entity other than the successor or purchasing company, as the case may be, in such Merger Event, then such other entity shall assume the obligations under this Agreement and any such assumption shall contain such
additional provisions to protect the interests of the Warrantholder as reasonably necessary by reason of the foregoing (as determined in good faith by the Company’s Board of Directors); provided, further, that the foregoing
assumption requirement shall not apply if (i) the consideration to be paid for or in respect of the outstanding shares of Preferred Stock in such Merger Event consists solely of cash and/or readily marketable securities, and (ii) the value
of such consideration (as determined at closing in accordance with the definitive executed transaction documents) to be paid for or in respect of each outstanding share of Preferred Stock is at least two (2) times the Exercise Price in effect
as of immediately prior to the closing of such Merger Event. In connection with a Merger Event and upon Warrantholder’s written election to the Company, the Company shall cause this Warrant Agreement to be exchanged for the consideration that
Warrantholder would have received if Warrantholder had chosen to exercise its right to have shares issued pursuant to the Net Issuance provisions of this Warrant Agreement without actually exercising such right, acquiring such shares and exchanging
such shares for such consideration. The provisions of this Section 8(a) shall similarly apply to successive Merger Events. 
 (b)
Reclassification of Shares. Without duplication of any adjustment made pursuant to Section 8(a), and subject to Section 8(f), if the Company at any time shall, by combination, reclassification, reorganization, exchange or
subdivision of securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes, this Agreement shall thereafter represent
the right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination,
reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall similarly apply to successive combination, reclassification, exchange, subdivision or other change. 

(c) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Preferred Stock, (i) in the
case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares of Preferred Stock issuable hereunder shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be
proportionately increased and the number of shares of Preferred Stock issuable hereunder shall be proportionately decreased. 

  
 5 








 (d) Stock Dividends. If the Company at any time while this Agreement is outstanding and
unexpired shall: 
 (i) pay a dividend with respect to the Preferred Stock payable in Preferred Stock, then the Exercise
Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of determination
by a fraction (A) the numerator of which shall be the total number of shares of Preferred Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of
Preferred Stock outstanding immediately after such dividend or distribution; or 
 (ii) make any other distribution with
respect to Preferred Stock (or stock into which the Preferred Stock is convertible), except any distribution specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such
that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the Preferred Stock (or other stock for which the Preferred Stock is convertible) as of
the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution. 
 (e) Antidilution
Rights. Additional antidilution rights applicable to the Preferred Stock purchasable hereunder are as set forth in the Charter and shall be applicable with respect to the Preferred Stock issuable hereunder. The Company shall promptly provide the
Warrantholder with any restatement, amendment, modification or waiver of the Charter; provided, that no such amendment, modification or waiver shall impair or reduce the antidilution rights applicable to the Preferred Stock unless such
amendment, modification or waiver affects the rights of Warrantholder with respect to the Preferred Stock in the same manner as it affects all other holders of Preferred Stock. The Company shall provide Warrantholder with written notice of any
issuance of its stock or other equity security to occur after the Effective Date of this Agreement (other than an issuance pursuant to the Company’s Incentive Plans or in connection with the exercise of outstanding derivative securities),
either prior to or promptly following such issuance, which notice shall include (a) the price at which such stock or security is to be or was sold, (b) the number of shares issued or to be issued, and (c) such other information as
necessary for Warrantholder to determine if a dilutive event has occurred. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment pursuant to this subsection (e), the forgoing subsection (d) and the Charter. 

(f) “Pay to Play” Rights. In the event that any “pay to play” terms or conditions (i.e. terms or conditions that
require a holder of the Preferred Stock to purchase securities in a future round of equity financing or else lose the benefit of anti-dilution protections applicable to shares of Preferred Stock or have such shares of Preferred Stock automatically
convert into common stock or another class or series of capital stock) in the Charter are triggered in connection with any offer, sale or issuance by the Company of its equity securities (a “Trigger Event”), then, in each such
event, the purchase rights under this Agreement shall automatically adjust to provide the Warrantholder, upon the later exercise hereof, with the same securities and/or rights that the Warrantholder would have received had the Warrantholder
(x) exercised this Warrant prior to such Trigger Event, and (y) participated in the applicable equity financing in an amount sufficient to be deemed to have fully participated for purposes of such “pay to play” provision. 

(g) Notice of Adjustments. If: (i) the Company shall declare or pay any dividend or distribution upon the outstanding shares of
Preferred Stock (or Common Stock if shares of Preferred Stock are then convertible into Common Stock) whether in stock, cash, or other property; (ii) the Company shall offer for subscription pro rata to the holders of the Preferred Stock or
other capital stock any additional shares of stock of any class or other rights; (iii) there shall be any Merger Event; (iv) there shall be an 

  
 6 








 
Initial Public Offering; (v) there shall be any voluntary or involuntary dissolution, liquidation or winding up of the Company, or (vi) there shall be an Initial Public Offering; then,
in connection with each such event, the Company shall send to the Warrantholder: (A) at least ten (10) days’ prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend,
distribution, subscription rights (specifying the date on which the holders of Preferred Stock shall be entitled thereto) or for determining rights to vote in respect of such Merger Event, dissolution, liquidation or winding up; (B) in the case
of any such Merger Event, at least ten (10) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders of Preferred Stock shall be entitled to exchange their Preferred Stock for
securities or other property deliverable upon such Merger Event, dissolution, liquidation or winding up); and (C) in the case of an Initial Public Offering, at least ten (10) days’ written notice prior to the effective date thereof.

 Each such written notice shall set forth, in reasonable detail, (i) the event requiring the notice, and (ii) if any adjustment is required to
be made, (A) the amount of such adjustment, (B) the method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and (D) the number of shares subject to purchase
hereunder after giving effect to such adjustment, and shall be given in accordance with Section 12(g) below. 
 (h) Timely
Notice. Failure to timely provide such notice required by subsection (g) above shall entitle Warrantholder to retain the benefit of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice
received by Warrantholder. For purposes of this subsection (h), and notwithstanding anything to the contrary in Section 12(g), the notice period shall begin on the date Warrantholder actually receives a written notice containing all the
information required to be provided in such subsection (g). 
 SECTION 9. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE
COMPANY. 
 (a) Reservation of Preferred Stock. The Preferred Stock issuable upon exercise of the Warrantholder’s rights has
been or, in the case of Preferred Stock issuable in the Next Equity Round, will be, duly and validly reserved and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and will be
free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Preferred Stock issuable pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The
Company has made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates for shares of Preferred Stock upon exercise of this Agreement shall be made without charge to the
Warrantholder for any issuance tax in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of Preferred Stock; provided, that the Company shall not be required to pay any
tax which may be payable in respect of any transfer and the issuance and delivery of any certificate in a name other than that of the Warrantholder. 

(b) Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company
hereunder, including the issuance to Warrantholder of the right to acquire the shares of Preferred Stock and the Common Stock into which it may be converted, have been duly authorized by all necessary corporate action on the part of the Company.
This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order applicable to it; and (3) does not and will not contravene any provision of,
or constitute a default under, any indenture, mortgage, contract or other instrument to which it is a party or by which it is bound, except to the extent that any such default does not have a material adverse effect on the Company. This Agreement
constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms. 
 (c) Consents and
Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and
performance by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time
required thereby. 

  
 7 








 (d) Issued Securities. All issued and outstanding shares of Common Stock, Preferred Stock
or any other securities of the Company have been duly authorized and validly issued and are fully paid and non-assessable. All outstanding shares of Common Stock, Preferred Stock and any other securities were issued in full compliance with all
federal and state securities laws. In addition, as of the date immediately preceding the date of this Agreement: 
 (i) The
authorized capital of the Company consists of (A) 25,525,727 shares of Common Stock, of which 8,760,000 shares are issued and outstanding, and (B) 11,527,280 shares of Preferred Stock, all of which have been designated as “Series A
Convertible Preferred Stock (8,516,100 of which are issued and outstanding and are convertible into 8,516,100 shares of Common Stock at $1.74 per share.) 

(ii) The Company has reserved 3,766,800 shares of Common Stock for issuance under its Stock Option Plan(s), under which
3,366,800 options are outstanding. Other than the foregoing options and 680,008 shares of Common Stock reserved for issuance upon exercise of a certain stock purchase warrant outstanding as of the date hereof, there are no other options, warrants,
conversion privileges or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s capital stock or other securities of the Company. The Company has no outstanding loans to any
employee, officer or director of the Company, and the Company agrees not to enter into any such loan or otherwise guarantee the payment of any loan made to an employee, officer or director by a third party. 

(iii) In accordance with the Company’s Charter, no shareholder of the Company has preemptive rights to purchase new
issuances of the Company’s capital stock. 
 (e) [Intentionally Omitted]. 

(f) Other Commitments to Register Securities. Except as set forth in this Agreement and one or more of the Stockholder Agreements, the
Company is not, pursuant to the terms of any other agreement currently in existence, under any obligation to register under the Act any of its presently outstanding securities or any of its securities which may hereafter be issued. 

(g) Exempt Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of the
Preferred Stock upon exercise of this Agreement, and the issuance of the Common Stock upon conversion of the Preferred Stock, will each constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in
reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state securities laws. 
 (h)
Compliance with Rule 144. At all times from and after consummation of the Initial Public Offering, if the Warrantholder proposes to sell Preferred Stock issuable upon the exercise of this Agreement, or the Common Stock into which it is
convertible, in compliance with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish to the Warrantholder, within ten days after receipt of such request, a written statement
confirming the Company’s compliance with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. 

(i) Information Rights. During the term of this Warrant, Warrantholder shall be entitled to the information rights contained in
Section 7.1 of the Loan Agreement, and Section 7.1 of the Loan Agreement is hereby incorporated into this Agreement by this reference as though fully set forth herein, provided, however, that the Company shall not be required to deliver a
Compliance Certificate once all Indebtedness (as defined in the Loan Agreement) owed by the Company to Warrantholder has been repaid. 

  
 8 








 (j) Registration Rights. The Company agrees that the shares of Common Stock issued and
issuable upon conversion of the shares of Preferred Stock issued and issuable upon exercise of this Warrant, and, at all times (if any) when the Preferred Stock shall be Common Stock, the shares of Preferred Stock issued and issuable upon exercise
of this Warrant, shall have the “Piggyback,” and S-3 registration rights pursuant to and as set forth in the Company’s Investor Rights Agreement or similar agreement on a pari passu basis with the holders of outstanding shares
of Preferred Stock who are parties thereto. The provisions set forth in the Company’s Investor Rights Agreement or similar agreement relating to such registration rights in effect as of the Effective Date may not be amended, modified or waived
without the prior written consent of the Warrantholder unless such amendment, modification or waiver affects the rights associated with the shares of Preferred Stock issued and issuable upon exercise hereof in the same manner as such amendment,
modification, or waiver affects the rights associated with all outstanding shares of Preferred Stock whose holders are parties thereto. 

SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 

(a) Investment Purpose. The right to acquire Preferred Stock is being, and the Preferred Stock issuable upon exercise of the
Warrantholder’s rights contained herein will be, acquired for investment and not with a view to the sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution of
such rights or the Preferred Stock except pursuant to an effective registration statement or an exemption from the registration requirements of the Act. 

(b) Private Issue. The Warrantholder understands (i) that the Preferred Stock issuable upon exercise of this Agreement is not
registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by this Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that the
Company’s reliance on such exemption is predicated on the representations set forth in this Section 10. 
 (c) Financial
Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 

(d) Risk of No Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to
Section 12 of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934 Act, or if a registration statement covering the securities under the Act is not in effect when it
desires to sell (i) the rights to purchase Preferred Stock pursuant to this Agreement or (ii) the Preferred Stock issuable upon exercise of the right to purchase, it may be required to hold such securities for an indefinite period. The
Warrantholder also understands that any sale of (A) its rights hereunder to purchase Preferred Stock or (B) Preferred Stock issued or issuable hereunder which might be made by it in reliance upon Rule 144 under the Act may be made only in
accordance with the terms and conditions of that Rule. 
 (e) Accredited Investor. Warrantholder is an “accredited
investor” within the meaning of the Securities and Exchange Rule 501 of Regulation D, as presently in effect. 
 SECTION 11.
TRANSFERS. 
 (a) General. Subject to compliance with applicable federal and state securities laws, this Agreement and all rights
hereunder are transferable, in whole or in part, without charge to the holder 

  
 9 








 
hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this
Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons
dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by
the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such
transfer. Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. Notwithstanding the foregoing: (i) any sale, assignment or other transfer of any shares of Preferred
Stock issued on exercise hereof is subject to the provisions of the Stockholder Agreements to which Warrantholder is then a party or is required by the terms of Section 3(c) above to become a party; and (ii) the Warrantholder shall obtain
the prior written consent of the Company to any transfer of, or grant of security interest in, this Agreement (or the Preferred Stock or Common Stock obtainable upon exercise hereof) to any person or entity that directly competes with the Company or
that is then engaged in material litigation adverse to the Company, in either case as reasonably determined in good faith by the Company’s Board of Directors. 

(b) Market Stand-off Agreement. Warrantholder hereby agrees that it will not, without the prior written consent of the managing
underwriter, during the period commencing on the date of the final prospectus relating to the Initial Public Offering and ending on the date specified by the Company and the managing underwriter (such period not to exceed l80 days, or such other
period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited
to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto; provided, however, that such period shall not exceed one hundred eighty (180) days in the event that the
Financial Industry Regulatory Authority has amended or repealed FINRA Rule 2711(f)(4), or has otherwise provided written interpretive guidance regarding such rule, in each case, so as to eliminate the prohibition of any broker, dealer, or member of
a national securities association from publishing or distributing any research report, with respect to an emerging growth company (as defined in the Jumpstart Our Business Startups Act of 2012)), (i) lend, offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, this Warrant or any shares of Preferred Stock issued on
exercise hereof held immediately prior to the effectiveness of the registration statement for the Initial Public Offering, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic
consequences of ownership of this Warrant or the shares of Preferred Stock issuable or issued on exercise hereof, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of shares of Preferred Stock
or other securities, in cash or otherwise. The foregoing provisions of this Section 11(b) shall not apply to the sale of any shares of Preferred Stock to an underwriter pursuant to an underwriting agreement. The underwriters in connection with
the Initial Public Offering are intended third party beneficiaries of this Section 11(b) and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Warrantholder further agrees to execute
such agreements as may be reasonably requested by the underwriters of the Initial Public Offering that are consistent with this Section 11(b) or that are necessary to give further effect thereto. In order to enforce the foregoing, the Company
may impose stop-transfer instructions with respect to this Warrant and the shares of Preferred Stock issuable and issued hereunder (and transferees and assignees thereof) until the end of such restricted period. The foregoing agreements of
Warrantholder in this Section 11(b) shall be effective only if all directors and officers of the Company, and all holders of one percent (1%) or more of the outstanding shares of Common Stock, (determined on a fully-diluted, as-exercised,
as-converted basis), shall have entered into and be bound by similar agreements with the Company and, if applicable, with such underwriters. 

  
 10 








 SECTION 12. MISCELLANEOUS. 

(a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been
executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by
suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at law and
where damages will not be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the Warrantholder or any other person entitled to the benefit of this Agreement requiring specific performance of any or all
provisions hereof or enjoining the Company from continuing to commit any such breach of this Agreement. 
 (c) No Impairment of
Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of
all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 

(d) Additional Documents. The Company shall also provide Warrantholder with such other documents and information concerning the Company
as Warrantholder may reasonably request from time to time. 
 (e) Attorneys’ Fees. In any litigation, arbitration or court
proceeding between the Company and the Warrantholder relating hereto, the prevailing party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement. For the purposes of this
Section 12(e), attorneys’ fees shall include without limitation fees incurred in connection with the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in
connection with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and proceedings of any kind, including without limitation any activity taken to collect or enforce any
judgment. 
 (f) Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid,
illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to
the intention of the parties underlying the invalid, illegal or unenforceable provision. 
 (g) Notices. Except as otherwise provided
herein, any notice, demand, request, consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and
shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time
zone of the recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter, or the first business day after deposit with an overnight express service or overnight mail delivery service;
or (ii) the third calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to the party to be notified as follows: 

If to Warrantholder: 
 HERCULES TECHNOLOGY III,
L.P. 
 Legal Department 

Attention: Chief Legal Officer and Manuel Henriquez 

400 Hamilton Avenue, Suite 310 

Palo Alto, CA 94301 
 Facsimile:
650-473-9194 
 Telephone: 650-289-3060 

  
 11 








 If to the Company: 

Dance Biopharma, Inc. 
 Attention:
Chief Financial Officer 
 2 Mint Plaza, Suite 804 

San Francisco, CA 94103 

Facsimile: 
 Telephone: 

or to such other address as each party may designate for itself by like notice. 

(h) Entire Agreement; Amendments. This Agreement constitute the entire agreement and understanding of the parties hereto in respect of
the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof (including
Lender’s proposal letter dated July 15, 2013). None of the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. 

(i) Headings. The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or
interpretation of this Agreement or any provisions hereof. 
 (j) [Intentionally Omitted] 

(k) No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. 
 (l) No Waiver. No omission or delay by Warrantholder at any time to enforce any
right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right or remedy to which Warrantholder is entitled, nor shall it in
any way affect the right of Warrantholder to enforce such provisions thereafter. 
 (m) Survival. All agreements, representations and
warranties contained in this Agreement or in any document delivered pursuant hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement.

 (n) Governing Law. This Agreement have been negotiated and delivered to Warrantholder in the State of California, and shall have
been accepted by Warrantholder in the State of California. Delivery of Preferred Stock to Warrantholder by the Company under this Agreement is due in the State of California. This Agreement shall be governed by, and construed and enforced in
accordance with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction. 

(o) Consent to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County,
State of California; (b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack of jurisdiction or venue in the aforesaid courts; and
(d) irrevocably agrees to be bound by any judgment rendered thereby in connection with this Agreement. Service of process on any 

  
 12 








 
party hereto in any action arising out of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall be
deemed effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other
jurisdiction. 
 (p) Mutual Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most
quickly and economically resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties desire that their disputes be resolved by a judge applying such
applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”)
ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons other than the Company and Warrantholder; Claims
that arise out of or are in any way connected to the relationship between the Company and Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind, arising out of this
Agreement. 
 (q) Judicial Reference. If the waiver of jury trial set forth above is ineffective or unenforceable, the parties agree
that all Claims shall be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding
Judge of Santa Clara County, California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable to such proceeding. 

(r) Prejudgment Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent
jurisdiction identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to
resolution by judicial reference. 
 (s) Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may
be executed in any number of counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

(t) Specific Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to
Warrantholder by reason of the Company’s failure to perform any of the obligations under this Agreement and agree that the terms of this Agreement shall be specifically enforceable by Warrantholder. 

[Remainder of Page Intentionally Left Blank] 

  
 13 








 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by its officers
thereunto duly authorized as of the Effective Date. 
  

									
	 COMPANY:
	 		 		 	DANCE BIOPHARM, INC.
					
		 		 		 	By:	 	 /s/ John Patton

					
		 		 		 	Name:	 	John Patton
					
		 		 		 	Title:	 	CEO and Chairman
				
	WARRANTHOLDER:	 		 		 	HERCULES TECHNOLOGY III, L.P.,
		 		 		 	a Delaware limited partnership
					
		 		 		 	By:	 	Hercules Technology SBIC Management, LLC,
		 		 		 		 	its General Partner
					
		 		 		 	By:	 	Hercules Technology Growth Capital, Inc.,
		 		 		 		 	its Manager
					
		 		 		 	By:	 	 /s/ Ben Bang

		 		 		 	Name:	 	Ben Bang
		 		 		 	Title:	 	Senior Counsel


  
 14 








 EXHIBIT I 

NOTICE OF EXERCISE 
  

	To:	[                                    
    ] 

  

	(1)	The undersigned Warrantholder hereby elects to purchase [            ] shares of the Series [    ] Preferred Stock/Common Stock of
[                    ], pursuant to the terms of the Agreement dated the [    ] day of
[        ,         ] (the “Agreement”) between
[                    ] and the Warrantholder, and [CASH PAYMENT: tenders herewith payment of the Purchase Price in full, together with all applicable
transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a) of the Agreement to effect a Net Issuance.] 

  

	(2)	Please issue a certificate or certificates representing said shares of Series [    ] Preferred Stock/Common Stock in the name of the undersigned or in such other name as is specified below.


  

									
		 		 		 		 	
		 		 		 	  
 (Name)

				
		 		 		 	  
 (Address)

				
	WARRANTHOLDER:	 		 		 	HERCULES TECHNOLOGY III, L.P.,
		 		 		 	a Delaware limited partnership
					
		 		 		 	By:	 	Hercules Technology SBIC Management, LLC,
		 		 		 		 	its General Partner
					
		 		 		 	By:	 	Hercules Technology Growth Capital, Inc.,
		 		 		 		 	its Manager
					
		 		 		 	By:	 	  

		 		 		 	Name:	 	Ben Bang
		 		 		 	Title:	 	Senior Counsel
					
		 		 		 	Date:	 	  



  
 15 








 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 
 The undersigned
[                                        ],
hereby acknowledge receipt of the “Notice of Exercise” from Hercules Technology III, L.P., to purchase [            ] shares of the Series [    ] Preferred
Stock/Common Stock of [                    ], pursuant to the terms of the Agreement, and further acknowledges that
[            ] shares remain subject to purchase under the terms of the Agreement. 
  

									
	 COMPANY:
	 		 		 	[                    ]
					
		 		 		 	By:	 	  

					
		 		 		 	Title:	 	  

					
		 		 		 	Date:	 	  



  
 16 








 EXHIBIT III 

TRANSFER NOTICE 
 (To transfer or assign the
foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 
 FOR VALUE RECEIVED, the foregoing
Agreement and all rights evidenced thereby are hereby transferred and assigned to 
  

					
	  
	  	
	(Please Print)	  		  	
			
	whose address is	  	  
	  	
		
	  
	  	

  

					
		 	Dated:	 	  



					
			
		 	Holder’s Signature:	 	  



					
			
		 	Holder’s Address:	 	  

		
		 	  


  

					
	Signature Guaranteed:	 	  
	  	

 NOTE: The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement,
without alteration or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 17